(Q46555595)

20 February 2018

title

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations (English)

1 reference

20 February 2018

Daniel Sanghoon Shin

0 references

Bartosz Chmielowski

1 reference

20 February 2018

Antoni Ribas

1 reference

20 February 2018

Begoña Comin-Anduix

1 reference

20 February 2018

Nicolaos Palaskas

0 references

Anusha Kalbasi

0 references

Luis A Diaz

0 references

Siwen Hu-Lieskovan

1 reference

20 February 2018

Beata Berent-Maoz

object named as

Beata Berent-Maoz

1 reference

20 February 2018

author name string

Jesse M Zaretsky

1 reference

20 February 2018

Helena Escuin-Ordinas

1 reference

20 February 2018

Angel Garcia-Diaz

1 reference

20 February 2018

Catherine S Grasso

1 reference

20 February 2018

Willy Hugo

1 reference

20 February 2018

Salemiz Sandoval

1 reference

20 February 2018

Davis Y Torrejon

1 reference

20 February 2018

Gabriel Abril Rodriguez

1 reference

20 February 2018

Giulia Parisi

1 reference

20 February 2018

Ariel Azhdam

1 reference

20 February 2018

Grace Cherry

1 reference

20 February 2018

Elizabeth Seja

1 reference

20 February 2018

I Peter Shintaku

1 reference

20 February 2018

Dung T Le

1 reference

20 February 2018

Drew M Pardoll

1 reference

20 February 2018

Paul C Tumeh

1 reference

20 February 2018

Thomas G Graeber

1 reference

20 February 2018

Roger S Lo

1 reference

20 February 2018

publication date

30 November 2016

1 reference

20 February 2018

published in

Cancer Discovery

1 reference

20 February 2018

volume

1 reference

20 February 2018

issue

1 reference

20 February 2018

page(s)

188-201

1 reference

20 February 2018

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Pembrolizumab for the treatment of non-small-cell lung cancer

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Pembrolizumab versus Ipilimumab in Advanced Melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

The future of immune checkpoint therapy

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Oncotator: cancer variant annotation tool

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

PD-1 blockade induces responses by inhibiting adaptive immune resistance

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Nivolumab in previously untreated melanoma without BRAF mutation

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

COX-2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

The blockade of immune checkpoints in cancer immunotherapy

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Mechanisms of type-I- and type-II-interferon-mediated signalling

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFNgamma-induced apoptosis.

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Cancer immunoediting: from immunosurveillance to tumor escape

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

The IFN gamma receptor: a paradigm for cytokine receptor signaling

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway

24 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5296316

10.1158/2159-8290.CD-16-1223

24 May 2018

Identifiers

DOI

1 reference

20 February 2018

PMC publication ID

5296316

1 reference

20 February 2018

PubMed publication ID

27903500

1 reference

20 February 2018